Everest Organics Ltd (EVERESTO) — shareholding pattern, promoter holding, financials and share price
About Everest Organics Ltd (EVERESTO)
Everest Organics Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as EVERESTO and on the BSE under scrip code 524790. Its ISIN is INE334C01029.
Incorporated in 1993, Everest Organics Ltd manufactures APIs and Intermediates. [1]
Everest Organics Ltd is primarily engaged in the manufacturing of Active Pharmaceutical Ingredients and intermediaries, with operations commencing in 1993.
The company had set up a plant in Andhra Pradesh focusing initially on bulk drugs and formulations, with a public issue in 1995 to fund its growth.
Listed peers in Pharmaceuticals: Medicamen Biotech Ltd, Medico Remedies Ltd, Infinium Pharmachem Ltd, Trident Lifeline Ltd, BDH Industries Ltd, Astonea Labs Ltd.
Valuation & Returns
10 Jul 2026At ₹312 a share on 10 Jul 2026, Everest Organics Ltd (EVERESTO) was valued at a price-to-earnings ratio of 54.49x against an industry P/E of 36.41x and a price-to-book of 4.33x on a book value of ₹72.03 per share as of Mar 2025. Solomo computes return on equity of 7.95% and return on capital employed of 12.37% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 54.49x
- Industry P/E
- 36.41x
- P/B
- 4.33x
- EPS (TTM)
- ₹5.73
- Book value / share
- ₹72.03
- ROE
- 7.95%
- ROCE
- 12.37%
- ROA
- 2.48%
- Debt / equity
- 0.68x
- Dividend yield
- 0%
- EBITDA margin
- 10.74%
- 52-week range
- ₹197 – ₹536.4
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Everest Organics Ltd (EVERESTO) reported revenue of ₹196 crore, net profit of ₹6 crore and earnings per share of ₹5.72. That compares with revenue of ₹159 crore and net profit of ₹-1 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹48.75 crore and net profit ₹2.63 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 200 | 183 | 197 | 159 | 196 |
| Net profit (₹ cr) | 1 | 0 | 0 | -1 | 6 |
| EPS (₹) | 1.42 | -0.22 | 0.18 | -1.33 | 5.72 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 5.94% | -0.78% | -7.47% | -19.14% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 59.6% of Everest Organics Ltd (EVERESTO) (up 0.02 pp QoQ) and domestic institutional investors (DII) hold 0.02%. Market capitalisation was ₹303 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: R VENKATA NARAYANA 7.52%, GREENPATH ENERGY PRIVATE LIMITED 7.44%, Unclaimed or Suspense or Escrow Account 1.86%, JAYANT PRASAD PALETI 1.32%, SAI PRASANNA MANCHINENI 1.02%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 59.6% | - | - | 0.02% | 40.4% |
| Mar 2026 | 59.58% | - | - | 0.02% | 40.42% |
| Dec 2025 | 59.61% | - | - | 0.02% | 40.39% |
| Sep 2025 | 59.64% | - | - | 0.02% | 40.36% |
| Jun 2025 | 60.99% | - | - | 0.02% | 39.01% |
| Mar 2025 | 61.09% | - | - | 0.02% | 38.91% |
| Dec 2024 | 74.15% | - | - | 0.05% | 25.85% |
| Sep 2024 | 74.15% | - | - | 0.05% | 25.85% |